title: A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
abstract: OBJECTIVE
  EZH2 expression is a prognostic marker in radically resected pancreatic ductal adenocarcinoma (PDAC) patients. Here we investigated its role in locally advanced/metastatic patients, as well as candidate polymorphisms.
  
  
  METHODS
  EZH2 expression and polymorphisms were evaluated by quantitative reverse transcription PCR in 32 laser microdissected tumors, while polymorphisms were also studied in blood samples from two additional cohorts treated with gemcitabine monotherapy (n = 93) or polychemotherapeutic regimens (n = 247).
  
  
  RESULTS
  EZH2 expression correlated with survival and with the rs6958683 polymorphism in the first cohort of patients, but this polymorphism was not associated with survival in our larger cohorts.
  
  
  CONCLUSIONS
  EZH2 is a prognostic factor for locally advanced/metastatic PDACs, while candidate polymorphisms cannot predict clinical outcome. Other factors involved in EZH2 regulation, such as miR-101, should be investigated in accessible samples in order to improve the clinical management of advanced PDAC.
authors.affiliation: Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, CCA room 1.52, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
authors.forename: Mina
authors.initials: M
authors.lastname: Maftouh
authors.forename: Amir
authors.initials: A
authors.lastname: Avan
authors.forename: Niccola
authors.initials: N
authors.lastname: Funel
authors.forename: Elisa
authors.initials: E
authors.lastname: Paolicchi
authors.forename: Enrico
authors.initials: E
authors.lastname: Vasile
authors.forename: Paola
authors.initials: P
authors.lastname: Pacetti
authors.forename: Vanja
authors.initials: V
authors.lastname: Vaccaro
authors.forename: Pinuccia
authors.initials: P
authors.lastname: Faviana
authors.forename: Daniela
authors.initials: D
authors.lastname: Campani
authors.forename: Sara
authors.initials: S
authors.lastname: Caponi
authors.forename: Andrea
authors.initials: A
authors.lastname: Mambrini
authors.forename: Ugo
authors.initials: U
authors.lastname: Boggi
authors.forename: Maurizio
authors.initials: M
authors.lastname: Cantore
authors.forename: Michele
authors.initials: M
authors.lastname: Milella
authors.forename: Godefridus J
authors.initials: GJ
authors.lastname: Peters
authors.forename: Michele
authors.initials: M
authors.lastname: Reni
authors.forename: Elisa
authors.initials: E
authors.lastname: Giovannetti
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D015331:Cohort Studies; D004247:DNA / Q000235:genetics; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D063151:Polycomb Repressive Complex 2 / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000235:genetics; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; C534072:MIRN101 microRNA, human; D035683:MicroRNAs; D003841:Deoxycytidine; D004247:DNA; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2; D000093542:Gemcitabine